Nuvectis Pharma, Inc.
NVCT
$8.76
-$0.04-0.46%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -39.17% | -30.98% | -4.57% | 9.92% | 14.65% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.17% | 15.39% | 9.94% | 7.20% | 3.25% |
| Change in Net Operating Assets | 132.24% | 543.35% | 147.70% | 40.93% | 18.36% |
| Cash from Operations | -30.72% | -6.37% | 14.25% | 22.35% | 23.24% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 159.31% | 288.64% | 165.43% | 16.27% | -26.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -449.74% | -785.12% | -183.78% | -38.74% | 72.60% |
| Cash from Financing | 149.79% | 274.89% | 163.98% | 15.01% | -22.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,309.27% | 473.68% | 233.82% | 160.26% | 31.60% |